Showing results (41-50 of 86) with videos related to
Sort By:
Pageof 9
Pathology, Research and Practice|May 13, 2025
Exploiting E3 ligases for lung cancer therapy: The promise of DCAF-PROTACsMd Sadique Hussain, Lina Eltaib, Amita Joshi Rana, et al.Drug Development and Industrial Pharmacy|January 6, 2025
Solid dispersion of alectinib HCl: preclinical evaluation for improving bioavailability and establishing an IVIVC modelSumit Kumar Saha, Vipin Arya, Ajinkya Jadhav, et al.Clinical Pharmacokinetics|April 5, 2013
An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancerDan Lu, Amita Joshi, Bei Wang, et al.Current Pharmaceutical Design|August 15, 2025
Exploring the Neurobiological Mechanisms of Cancer GrowthMd Sadique Hussain, Mudasir Maqbool, Mohit Agrawal, et al.Molecular Biotechnology|June 30, 2025
Transforming Hemophilia Management: Lessons from Gene Therapy Clinical TrialsMd Sadique Hussain, Mudasir Maqbool, Mohammed M Arab, et al.Investigative Ophthalmology & Visual Science|January 31, 2013
Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approachLu Xu, Tong Lu, Lisa Tuomi, et al.British Journal of Clinical Pharmacology|August 7, 2024
Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European UnionRui Zhu, Rik Schoemaker, Aurelie Gautier, et al.Journal of Clinical Pharmacology|January 7, 2006
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasisAmita Joshi, Robert Bauer, Peter Kuebler, et al.Current Pharmaceutical Design|March 1, 2026
Unlocking the Role of Exosomal ncRNAs in Colorectal Cancer: Molecular Insights and Clinical PromiseLina Eltaib, Liming Zhang, Yumna Khan, et al.Cancer Chemotherapy and Pharmacology|January 27, 2016
A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activitiesDan Lu, Tong Lu, Mark Stroh, et al.Pageof 9